- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 239/26
Total number of patents in this class: 1131
10-year publication summary
|
111
|
88
|
91
|
80
|
90
|
78
|
81
|
79
|
57
|
39
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| LG Chem, Ltd. | 17986 |
58 |
| Solus Advanced Materials Co., Ltd. | 263 |
35 |
| Bristol-myers Squibb Company | 4747 |
27 |
| Merck Patent GmbH | 5751 |
22 |
| Novaled GmbH | 492 |
21 |
| Idemitsu Kosan Co., Ltd. | 4298 |
19 |
| Shaanxi Lighte Optoelectronics Material Co., Ltd. | 327 |
17 |
| Semiconductor Energy Laboratory Co., Ltd. | 11896 |
16 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3361 |
16 |
| Nodthera Limited | 45 |
14 |
| Amgen Inc. | 4483 |
13 |
| Novartis AG | 10170 |
12 |
| BASF SE | 21334 |
12 |
| JNC Corporation | 1556 |
11 |
| Tosoh Corporation | 1440 |
11 |
| UCB Biopharma SRL | 595 |
11 |
| Nxera Pharma UK Limited | 185 |
11 |
| Abbvie Inc. | 1812 |
10 |
| JNC Petrochemical Corporation | 328 |
10 |
| Samsung Display Co., Ltd. | 39229 |
9 |
| Other owners | 776 |